These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1508821)

  • 1. Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: a comparison between MESNA and ARGIMESNA.
    Pea F; Mazzo M; Miglioli PA; Casiglia E; Pessina A; Moretti V
    Pharmacol Res; 1992; 25 Suppl 1():85-6. PubMed ID: 1508821
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of L-arginine mono(2-mercaptoethanesulfonate) on the ischemic and reperfused heart.
    Cargnoni A; Comini L; Boraso A; De Giuli F; Scotti C; Ferrari R
    Cardioscience; 1992 Sep; 3(3):179-87. PubMed ID: 1420954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
    Shaw IC; Weeks MS
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
    Reuther H; Kohl M; Wildenauer DB
    Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Ormstad K; Orrenius S; Låstbom T; Uehara N; Pohl J; Stekar J; Brock N
    Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
    J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral bioavailability of mesna tablets.
    Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
    Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
    James CA; Mant TG; Rogers HJ
    Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
    el-Yazigi A; Yusuf A; al-Rawithi S
    Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of orally administered mesna.
    Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
    Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fate of [14C]-mesna in the rat.
    Shaw IC; Graham MI; Jones MS
    Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stability of mesna in beverages and syrup for oral administration.
    Goren MP; Lyman BA; Li JT
    Cancer Chemother Pharmacol; 1991; 28(4):298-301. PubMed ID: 1908750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection.
    James CA; Rogers HJ
    J Chromatogr; 1986 Oct; 382():394-8. PubMed ID: 3097045
    [No Abstract]   [Full Text] [Related]  

  • 15. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
    Mohrmann M; Ansorge S; Schönfeld B; Brandis M
    Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic and non-enzymatic mechanisms of dimesna metabolism.
    Cutler MJ; Velenosi TJ; Bodalia A; House AA; Urquhart BL; Freeman DJ
    Amino Acids; 2015 Mar; 47(3):511-23. PubMed ID: 25488427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of dimesna to mesna by the isolated perfused rat liver.
    Goren MP; Hsu LC; Li JT
    Cancer Res; 1998 Oct; 58(19):4358-62. PubMed ID: 9766664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
    Roth B; Cerny T; Brunner KW; Küpfer A
    Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.